Akero Therapeutics (AKRO) Price & Analysis

Compare

641 Followers

AKRO Stock Chart & Stats

$54.31

-$0.52(-1.95%)

At close: Jan 08 4:00 PM EST

$54.31

-$0.52(-1.95%)

Day’s Range― - ―

52-Week Range$21.34 - $58.40

Previous CloseN/A

Volume136.04K

Average Volume (3M)3.37M

Market Cap

$4.47B

Enterprise Value$3.16B

Total Cash (Recent Filing)$737.83M

Total Debt (Recent Filing)$1.16M

Price to Earnings (P/E)―

Beta0.59

Next Earnings

Mar 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.99

Shares Outstanding82,316,180

10 Day Avg. Volume1,581,662

30 Day Avg. Volume3,372,202

Financial Highlights & Ratios

PEG Ratio-0.25

Price to Book (P/B)2.49

Price to Sales (P/S)0.00

P/FCF Ratio-8.12

Enterprise Value/Market Cap0.71

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-10.96

Forecast

1Y Price Target

$60.25

Price Target Upside10.94% Upside

Rating ConsensusHold

Number of Analyst Covering9

EPS Forecast (FY)-3.8

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementsAkero's lead asset, efruxifermin (EFX), has shown best-in-class clinical data across F2-F4, enhancing its value in the acquisition.

Shareholder ValueThe deal offers AKRO shareholders a significant premium, providing a 19% premium to the 30-day VWAP and 42% premium to the closing stock price.

Strategic AcquisitionThe acquisition by Novo Nordisk is seen as a logical move that could bolster its position in the metabolic treatment landscape.

Bears Say

Analyst DowngradeAnalyst recommendation has been downgraded to Hold, indicating a more cautious stance on the stock following the acquisition announcement.

Development ChallengesNovo discontinued development of its own FGF21 analog, zalfermin, after disappointing Phase II data in F2-4 MASH.

Valuation ReassessmentThe price target for AKRO has been decreased based on the deal terms, suggesting a reassessment of the company's valuation.

Akero Therapeutics News

Akero Therapeutics announces new findings from SYMMETRY, HARMONY trials

Akero Therapeutics (AKRO) announced new findings from the SYMMETRY and HARMONY Phase 2b trials of efruxifermin in patients...

15d ago

AKRO

Hold Rating for Akero Therapeutics Amid SYNCHRONY MASH Progress and Novo Nordisk Acquisition

TD Cowen analyst Ritu Baral has maintained their neutral stance on AKRO stock, giving a Hold rating today....

9d ago

AKRO

Akero Therapeutics (AKRO) Q3 Earnings Cheat Sheet

Akero Therapeutics (AKRO) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street analysts...

13d ago

AKRO

Akero Therapeutics’ Phase 3 Study on Efruxifermin: A Potential Game-Changer for NASH/MASH Treatment

Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3...

26d ago

AKRO

Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?

Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Study Overview: Akero Therapeutics is conducting a...

26d ago

AKRO

Akero Therapeutics downgraded to Hold from Buy at TD Cowen

TD Cowen downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $58, down from...

1M ago

AKRO

Hold Rating on Akero Therapeutics Amid NOVO Acquisition and Regulatory Uncertainties

Akero Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from...

1M ago

AKRO

Madrigal Pharmaceuticals price target raised to $590 from $500 at Oppenheimer

Oppenheimer analyst Jay Olson raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $590 from $500 and...

1M ago

NVO

AKRO

Akero Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Akero Therapeutics (AKRO) to Neutral from Buy with a price target of $54, down from...

1M ago

AKRO

Akero Therapeutics downgraded to Hold from Buy at Clear Street

Clear Street downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $54, up from...

1M ago

NVO

AKRO

Akero Therapeutics Acquired by Novo Nordisk for $5.2B

The latest announcement is out from Akero Therapeutics ( ($AKRO) ). On October 9, 2025, Akero Therapeutics announced...

1M ago

AKRO

Akero Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research analyst Andy Chen downgraded Akero Therapeutics (AKRO) to Peer Perform from Outperform following Novo Nordisk’s (NVO)...

1M ago

AKRO

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Earnings reports, deals, and a stock market warning make up the top market stories on Thursday. ...

1M ago

AMD

DAL

Akero Therapeutics rises 16.6%

Akero Therapeutics (AKRO) is up 16.6%, or $7.74 to $54.23. Published first on TheFly – the ultimate source...

1M ago

AKRO

AKRO FAQ

What was Akero Therapeutics Inc’s price range in the past 12 months?

Akero Therapeutics Inc lowest stock price was $21.34 and its highest was $58.40 in the past 12 months.

What is Akero Therapeutics Inc’s market cap?

Akero Therapeutics Inc’s market cap is $4.47B.

When is Akero Therapeutics Inc’s upcoming earnings report date?

Akero Therapeutics Inc’s upcoming earnings report date is Mar 12, 2026 which is in 110 days.

How were Akero Therapeutics Inc’s earnings last quarter?

Akero Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.995 earnings per share for the quarter, missing the consensus estimate of -$0.952 by -$0.043.

Is Akero Therapeutics Inc overvalued?

According to Wall Street analysts Akero Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akero Therapeutics Inc pay dividends?

Akero Therapeutics Inc does not currently pay dividends.

What is Akero Therapeutics Inc’s EPS estimate?

Akero Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Akero Therapeutics Inc have?

Akero Therapeutics Inc has 82,316,180 shares outstanding.

What happened to Akero Therapeutics Inc’s price movement after its last earnings report?

Akero Therapeutics Inc reported an EPS of -$0.995 in its last earnings report, missing expectations of -$0.952. Following the earnings report the stock price went up 0.092%.

Which hedge fund is a major shareholder of Akero Therapeutics Inc?

Currently, no hedge funds are holding shares in AKRO

Akero Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-34.53%

Trailing 12-Months

Asset Growth

23.00%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Akero Therapeutics Inc

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Akero Therapeutics (AKRO) Earnings & Revenues

Historic Earnings Reports

AKRO Stock 12 Month Forecast

Average Price Target

$60.25

▲(10.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","40":"$40","55":"$55","70":"$70","85":"$85"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$84.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,40,55,70,85],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.2,56.4923076923077,58.784615384615385,61.07692307692308,63.36923076923077,65.66153846153847,67.95384615384616,70.24615384615385,72.53846153846155,74.83076923076923,77.12307692307692,79.41538461538462,81.70769230769231,{"y":84,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.2,54.66538461538462,55.13076923076923,55.59615384615385,56.06153846153846,56.526923076923076,56.99230769230769,57.45769230769231,57.92307692307693,58.38846153846154,58.853846153846156,59.31923076923077,59.784615384615385,{"y":60.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.2,54.184615384615384,54.16923076923077,54.15384615384615,54.13846153846154,54.12307692307692,54.10769230769231,54.09230769230769,54.07692307692308,54.06153846153846,54.04615384615385,54.03076923076923,54.01538461538462,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.82,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.44,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >